In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

BenevolentAI closes $115mm early equity round

Executive Summary

In what appears to be a Series B round, BenevolentAI (digital healthcare platform that uses artificial intelligence (AI) for drug discovery and development) raised $115mm (at a pre-money valuation of $2bn) from new investors as well as existing backers, including Woodford Investment Management. Credit Suisse was the placement agent.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Digital Health
    • Artificial Intelligence
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies